exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088545 RNA Name: hsa-miR-4485-3p RNA Type: miRNA Chromosome: chr11 Starnd: - Coordinate: Start Site(bp): 10508277 End Site(bp): 10508296 External Links: hsa-miR-4485-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand C11orf24 chr11 68261338 68272001 - CDK4 chr12 57747727 57756013 - CKAP5 chr11 46743048 46846308 - CYB561A3 chr11 61348745 61362299 - SERINC1 chr6 122443351 122471807 - NES chr1 156668763 156677407 - NDUFB11 chrX 47142216 47145504 - FUBP1 chr1 77944055 77979110 - RPL27 chr17 42998273 43002959 + YEATS2 chr3 183697797 183812624 + CIRBP chr19 1259384 1274880 + DNM1 chr9 128191655 128255248 + MAP3K11 chr11 65597756 65615382 - RPL13 chr16 89560657 89566828 + EXOSC6 chr16 70246778 70251940 - SBF2 chr11 9778667 10294207 - HSPA8 chr11 123057489 123063230 - RPS27A chr2 55231903 55235853 + EIF3F chr11 7970251 8001862 + RNASEH2C chr11 65714005 65720818 - FAU chr11 65120630 65122177 - HSP90AB1 chr6 44246166 44253888 + RPS3 chr11 75399515 75422280 + NR3C1 chr5 143277931 143435512 - SPG11 chr15 44562696 44663678 - MTRNR2L6 chr7 142666272 142667718 + LGR4 chr11 27365961 27472790 - FRMD8 chr11 65386621 65413525 + CRTC3 chr15 90529923 90645345 + MTRNR2L12 chr3 96617188 96618236 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand MALAT1 chr11 65497688 65506516 + XIST chrX 73820649 73852723 - AD000090.1 chr19 35557956 35581954 + LINC01002 chr19 198264 246544 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.